EP0127468A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Percutaneous pharmaceutical preparations for external use
Assignee: Sanofi Aventis Deutschland GmbH
•
Filing: 1984-05-25
•
Granted: —
•
Expires: 2004-05-25
Abstract
Abstract A percutaneous pharmaceutical preparation for external use containing N-ethoxycarbonyl -3- morpholinosydnon- imine (molsidomine) and an absorption promoter selected from the group consisting of aliphatic monoalcohols of 10 to 22 carbon atoms, aliphatic monoamides of 8 to 18 carbon atoms and aliphatic monoamines of 10 to 16 carbon atoms gives a high blood concentration of molsidomine over a long time period when applied to the human skin.
Inventors
- 👤 Masayuki Yamada
- 👤 Yoshiaki Uda
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 09:43
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/70; A61K9/7023; A61K9/703; A61K9/7084; A61K31/00; A61K31/33; A61K31/395; A61K31/535; A61K47/00; A61K47/06; A61K47/08; A61K47/10; A61K47/12; A61K47/16; A61K47/18; A61K9/0012; A61K9/0014; A61P; A61P9/00; A61P9/08
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
56 words
A percutaneous pharmaceutical preparation for external use which comprises N-ethoxycarbonyl-3-morpholinosydnonimine and at least an absorption promoter selected from the group consisting of aliphatic monocarboxylic acids of 5 to 30 carbon atoms, aliphatic monoalcohols of 10 to 22 carbon atoms, aliphatic monoamides of 8 to 18 carbon atoms and aliphatic monoamines of 10 to 16 carbon atoms.
Claim 2
Dependent Claim
56 words
A percutaneous pharmaceutical preparation for external use which comprises N-ethoxycarbonyl-3-morpholinosydnonimine and at least an absorption promoter selected from the group consisting of aliphatic monocarboxylic acids of 5 to 30 carbon atoms, aliphatic monoalcohols of 10 to 22 carbon atoms, aliphatic monoamides of 8 to 18 carbon atoms and aliphatic monoamines of 10 to 16 carbon atoms.
Claim 3
Dependent Claim
24 words
A percutaneous pharmaceutical preparation claimed in Claim 1, wherein the proportion of the absorption promoter is at least 0.01 weight part relative to N-ethoxycarbonyl-3-morpholinosydnonimine.
Claim 4
Dependent Claim
34 words
A percutaneous pharmaceutical preparation claimed in Claim 1, wherein the proportion of N-ethoxycarbonyl-3-morpholinosydnonimine and the absorption promoter to the whole preparation are 0.1 to 40% by weight and more than 0.1% by weight, respectively.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.